Quick Takeaways
- Deep Track Capital, LP filed SCHEDULE 13G for Aclaris Therapeutics, Inc. Common Stock, $0.00001 par value (ACRS).
- Disclosed ownership: 7%.
- Date of event: 09 Mar 2026.
Deep Track Capital, LP - 09 Mar 2026 SCHEDULE 13G Report for Aclaris Therapeutics, Inc. Common Stock, $0.00001 par value (ACRS)
- Filing Manager
- Deep Track Capital, LP
- Reporting Manager
- Deep Track Capital, LP
- Symbol
- ACRS
- Shares outstanding
- 133,500,000 shares
- Disclosed Ownership
- 9,345,000 shares
- Ownership
- 7%
- Form type
- SCHEDULE 13G
- Filing time
- 17 Mar 2026, 16:16:51 UTC
- Date of event
- 09 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"Deep Track Capital, LP disclosed 7% ownership in Aclaris Therapeutics, Inc. Common Stock, $0.00001 par value (ACRS) on 09 Mar 2026."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 17 Mar 2026, 16:16.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Deep Track Capital, LP | 7% | 9,345,000 | 0 | 9,345,000 | /s/ David Kroin | David Kroin, Managing Member of the General Partner of the Investment Adviser | |
| Deep Track Biotechnology Master Fund, Ltd. | 7% | 9,345,000 | 0 | 9,345,000 | /s/ David Kroin | David Kroin, Director | |
| David Kroin | 7% | 9,345,000 | 0 | 9,345,000 | /s/ David Kroin | David Kroin |